Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

JHOP - October 2021 Vol 11, No 5

Urine Alkalinization and Methotrexate Clearance: Are These Key to Safe Administration of High-Dose Methotrexate?

Joseph Bubalo, PharmD, BCPS, BCOP

Case Reports

Successful Treatment of Nivolumab plus Ipilimumab–Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine

Parikshit Padhi, MD, MBBS; Traci M. White, PharmD, PhC, BCGP; Neslihan Cetin, MD

Original Article

Outcomes of Pharmacist-Provided Telehealth Services in an Ambulatory Oncology Clinic During the COVID-19 Pandemic

Colleen Bohnenkamp, PharmD, BCOP, BCPS; Grace A. Martin, PharmD, BCOP; Laure Dubois, PharmD, BCOP; Olivia Fahey, PharmD, BCOP; Jade Hefler, PharmD

Tolerance of Oral Targeted Therapies in Patients with Metastatic Renal-Cell Carcinoma and Renal Impairment

Jessica McKernan, PharmD, BCOP; Laura Schmidt, PharmD, BCOP; Melissa Rhoades, PharmD, BCOP

Efficacy of an Enteral Urine Alkalinization Strategy During Intravenous Sodium Bicarbonate Shortage in Patients with Cancer Receiving High-Dose Methotrexate

Christopher Sinoimeri, PharmD; Matthew Lei, PharmD, BCOP; Stephanie Monaco, PharmD, BCOP; Uvette Lou, PharmD, BCOP

Review Article

Recent Targeted Therapies Approved for the Treatment of Patients with Urothelial Carcinoma

Bojana Stevich-Heemer, MS, PharmD, MEd, BCOP

FDA Oncology Update

Online First

Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer

Online First

Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations

Online First

Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease

Online First

Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-Versus-Host Disease

Online First

Jakafi a New Treatment Option for Chronic Graft-Versus-Host Disease

Online First

Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer

Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia

Online First

Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors

Online First

Lenvima plus Keytruda a New Combination Approved for Advanced Renal-Cell Carcinoma